The use of micafungin in neonates and children: A systematic review by Secinaro, Silvana Filomena et al.
European journal of volunteering and community-based projects Vol.1, No 1; 2020 
ISSN: 2724-0592 
Published by Odv Casa Arcobaleno 
100 
 
 
The use of micafungin in neonates and children: A systematic review 
Silvana Secinaro 
Department of Management, University of Turin, Turin, Italy e-mail: 
silvana.secinaro@unito.it 
Valerio Brescia 
Department of Management, University of Turin, Turin, Italy e-mail: 
valerio.brescia@unito.it 
Davide Calandra 
Department of Management, University of Turin, Turin, Italy e-mail: 
davide.calandra@unito.it 
Giovanni P. Verardi 
Ospedale Pediatrico Bambino Gesù, Rome, Italy, e-mail: 
gparide.verardi@opbg.net 
Fabrizio Bert 
Department of Public Health Service, University of Turin, Turin, Italy, e-mail: 
fabrizio.bert@unito.it 
 
Abstract 
About 10% of newborns under 1000 g have problems related to candidiasis. The 
mortality rate is still very high today, and new types of drugs are used for the treatment. 
To this end, the researcher conducts a systematic review concerning the clinical use of 
the micafungin drug in children and its impact regarding cost-effectiveness. The 
research used the PRISMA statements methodology to include all clinical and 
economic findings concerning the treatment of candidiasis through micafungin in 
infants and children. The research considers 13 clinical sources related to the use of 
micafungin belonging to the echinocandin family and a source of an economic nature. 
As highlighted by the research, micafungin is used in neonates for candida treatment 
with doses ranging from 0.4 to 10 mg/kg/ day on average for 15 days, and in children, 
the dose decreases slightly between 0.8 and 7.7 mg/kg/ day with a treatment period 
between 5 and 45 days. The use and efficacy of micafungin are features validated by 
several international clinical trials, success rates and conclusions confirm its validity. 
The analysis present in the literature on costs highlights how this disease is associated 
with higher costs due to the high number of days of hospitalization and for the 
administration of the drug. 
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1. Introduction 
Candidiasis management can occur using different pharmaceutical therapies. 
According to the paper by Santolaya et al. (Santolaya et al., 2013; Santolaya Maria E. 
et al., 2013), the choice is based on the clinical background of the individual patient, 
the level of disease spread and the existence of other risk factors. Several drugs can be 
used in the treatment of candida. The first type refers to medications belonging to the 
antimycotic class of triazole, which includes fluconazole which is administered orally 
(Greenberg & Benjamin, 2014). The further possibility is given by antifungal therapies 
(caspofungin, anidulafungin, and micafungin). 
In particular, micafungin is a semi-synthetic lipopeptide antifungal, it belongs to the 
class of echinocandins (Sucher et al., 2009) and it is produced by modifying the 
fermentation of "Coleophoma empetri" (Buck M., 2014). Its use is implemented in 
newborns and pediatric children with candidiasis by intravenous infusion throughout 
60 minutes. The single daily dose of the drug allows to have a low rate of adverse events 
in patients (Smith et al., 2009). The drug has been shown to have a broad spectrum of 
efficacy against candida  (Manzoni et al., 2014).  
Patients with candida generally present a clinical picture aggravated by low 
immunocompetent defences. For this reason, often the medical staff is forced to 
invasive procedures such as the using of external oxygen, central venous catheters, 
endotracheal tubes, broad-spectrum antibiotics, high doses of corticosteroids (Manzoni 
et al., 2014).  
In newborns, the most severe risk cause for candidiasis is age (Santolaya et al., 2013). 
The incidence of the disease for newborns weighing less than 1000 g is around 10% 
(Benjamin et al., 2010); the mortality rate in the case of age <28 weeks and <1000 g is 
between 40-50% of cases (Benjamin et al., 2004, 2006; Makhoul et al., 2002).  
For children older than 28 weeks and up to 18 years, the main risk factor for candidiasis 
infection is cancer (Blyth et al., 2009). In addition to this, the disease occurs in the case 
of prolonged treatments that cause severe mucositis neutropenia, patients undergoing 
induction of acute myeloid leukemia, non-Hodgkin's lymphoma, patients in post-
transplantation of bone marrow with a myeloablative regimen (Santolaya Maria E. et 
al., 2013).  An increased risk can also be brought about by inherited immune disorders 
(Hill, 1998). For this evidence, candidiasis is one of the significant causes of morbidity 
and mortality, particularly in the case of invasive candidiasis (Steinbach, 2016). 
For this evidence, candidiasis is one of the significant causes of morbidity and 
mortality, particularly in the case of invasive candidiasis (Steinbach, 2016). 
One of the features of candidiasis in pediatric age is that it has higher rates of aggression 
towards subjects already in critical condition, this leads to a mortality rate of 10% (T. 
Zaoutis, 2010). 
This situation has a particular impact on the economic management aspects of 
healthcare companies. In many cases, the days of hospitalization are prolonged for an 
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average period of 21.1 days, which creates an average increase in hospital costs of $ 
39.331 (T. E. Zaoutis et al., 2005).  
The systematic review intends to give a clinical and economic vision to the use of 
micafungin in newborns and children under the age of 19. 
 
2. Materials and methods 
The systematic research was set up according to the criteria of the Preferred Reporting 
methodology items for Systematic reviews and Meta-Analyses (PRISMA) statements 
(Liberati et al., 2009).  
The search for results took place in October and November 2018 by questioning the 
PubMed and Scopus platforms. 
For the selection of results, the team independently used the following keywords: 
Micafungin AND Infants, Micafungin AND cost-effectiveness AND Infants, 
Micafungin AND costs AND Infants, Micafungin AND cost-effectiveness. 
The collection of references used the following criteria: 
-papers are written in Italian, English or Spanish; 
-publication date from 2005; 
-papers on patients of child and/or pediatric age, both clinical and economic; 
-reading of the title and the abstract. 
Inversely, the following exclusion criteria were used: 
-articles that consider the risk of infection exclusively and not the clinical and/or 
economic aspect; 
- articles with analysis exclusively for adults. 
The choice that has been made, due to the lack of cost-effectiveness analysis of the 
treatments, has been to include in the same article both clinical and economic elements. 
For the selection of clinical cases, the research team reported in Table 1 the information 
present in the sample of selected articles.  The Table shows the number of clinical cases 
analysed, the country, the population target divided among newborns or infants, the 
progress of the disease, the dose of the administered drug, additional information 
regarding the type of patient and weight (when available), the duration of the treatment, 
the success rate/conclusion of the study in question. 
The selection of causes related to the cost-effectiveness of micafungin treatment, in 
Table 2, included information regarding the country, the age of patients, the number of 
patients, the minimum and the maximum number of days of hospitalization and the 
minimum and maximum increase of costs incurred by hospitals. 
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3. Results 
Systematic research has obtained 599 results.  
After selecting the articles according to the inclusion criteria above, 22 sources were 
selected for full reading (Figure 1). Of these 8 were double; 14 articles were valid for 
inclusion in the systematic review (Arrieta et al., 2011; Bochennek et al., 2015; Buck 
M., 2014; Hope et al., 2010; Kawaguchi et al., 2009; Kobayashi et al., 2015; Kovanda 
et al., 2018; Maximova et al., 2017; Queiroz-Telles et al., 2008; Santolaya et al., 2013; 
Santolaya Maria E. et al., 2013; Smith et al., 2009; Styczynski et al., 2016).  
The selection of the keywords did not allow to find a sufficient study sample concerning 
the cost-effectiveness of the administration of micafungin in the case of infants and 
children. In one case, explicit reference is made to the issue of economic evaluation; 
the result will be presented in table 2. 
Figure 1. Flow of literature review 
 
Figure 1. Flow chart of the included and excluded studies. Information flow chart of 
the different steps of the systematic review. 
For a more proactive analysis, we believe it is useful to start with the target of the 
population as the reference benchmark (except for the case presented by Buck M. (Buck 
M., 2014), in which we will first refer to the subdivision of patients' weight). From this 
element it will then be possible to activate further verification elements that include the 
number of clinical cases, the degree of spread of the disease, the dose of the 
administration, the additional information (weight or presence of particularities in the 
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administration), duration of treatment, the rate successful with relative conclusion of 
the clinical trial. Finally, the year of publication of the results will be highlighted.  
First of all, the articles retrieved consider as “infants” the subjects between 3 days and 
28 weeks after birth. In this population, the presence of candidiasis provides a treatment 
between 0.4 and 10 mg/ kg/day. The treatment period is between 1 and 34 days with a 
more used treatment period of 15 days. The clinical trial establishes the good 
tolerability of the drug. It must be considered the heterogeneity of the studies. For 
example, the research of Arrieta et al. (Arrieta et al., 2011) includes 40 % of patients 
with neutropenia, while in other studies the range of weight of subjects examined was 
very different. In the analysis of Kawaguchi et al. (Kawaguchi et al., 2009) the range 
of weight was 579.3 g (± 80.5 g) with a while in the analysis of Kovanda et al. (Kovanda 
et al., 2018) it is between 0.5 and 4.8 kg.  
If the disease has a more advanced and systemic stage of development there is a 
remodeling of the treatments; in particular, the treatment involves a higher dosage 
between 8-15 mg/kg /day. Again, it must be taken into account the heterogeneity of 
studies retrieved. 
The research of Hope et al. (Hope et al., 2010) considering newborns with a weight 
between 640 g and 4615 g, the doses of micafungin administered are divided between 
loading dose equal to 15 mg/kg/day and 10 as loading dose equal to 10 mg/kg/day, the 
period of administration is between 5 and 45 days. The therapy did not present any 
adverse events. 
In the case of Maximova et al. (Maximova et al., 2017), the average weight is 3240 g 
with a treatment administered in patients three days after allogeneic stem cell 
transplantation the micafungin was administered for doses between 8 and 15 
mg/kg/day, the success rate of the therapy was equal to 78.20%. Santolaya et al. 
(Santolaya et al., 2013), instead, considered patients are weighing more than 1000 g, 
and the treatment in these subjects was given at a dose of 15 mg/day for seven days 
(Queiroz-Telles et al., 2008), the success rate of therapy was 57,10%.  
In case of suspected systemic infection, the dose is 15 mg/ kg/day, the weight of the 
newborns is 775 g with a treatment of 5 days (Smith et al., 2009). 
The sample of clinical trials concerning pediatric patients covers a period of birth from 
2 months to 18 years. In the case of candidiasis, the conventional treatment is between 
0.8 and 7.7 mg/ kg/day with a duration between 15 and 19.7 days. The success rate for 
Arrieta et al. (Arrieta et al., 2011) it is not shown but as the authors say, micafungin 
was well tolerated by children of all ages, for Kobayashi et al. (Kobayashi et al., 2015) 
is 88,20%, in the case of Queiroz-Terres et al. (Queiroz-Telles et al., 2008) is 72,90%.  
In evidence of increased invasiveness of candidiasis, research in the literature suggests 
a dose of micafungin ranging from 2 to 6 mg/ kg/day. Invasive candidiasis is usually 
associated with hospitalized patients who have undergone surgery and who have been 
given broad-spectrum antibiotics. Indeed, in the research of Santolaya Maria E. et al. 
(Santolaya Maria E. et al., 2013) the minimum dose that is administered is 2 mg/kg/day, 
but in case of non-response to treatment, it is possible to increase it with 4 mg/kg/day 
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others. This applies to patients weighing less than 40 kg, plus in this case, the successful 
treatment occurs 14 days after the first negative hemoculture. The duration of the 
treatment is between 14 and 313 days.  
Then there are clinical cases involving patients with pediatric hemato-oncology (PHO) 
and hematopoietic stem cell transplantation (HSCT). 
The research of Steinbach (Steinbach, 2016) considered patients with PHO. The 
administration of micafungin was made for doses ranging from 1 to 2 mg/kg/day for 11 
days; in 63 patients already treated for 4.2 months with acute leukemia therapy. The 
doses of micafungin administered in these patients ranged from 1 to 2 mg/kg/day for 
11 days, and the success rate was around 85%. Even, the research of Steinbach 
(Steinbach, 2016) included pediatric patients in HSCT, the therapy based on 
micafungin is between 1 and 2 mg/kg/day for a period of administration of 15 days.  In 
that study, the 30 patients came from 2.3 months of treatment for HSCT, and the success 
rate of micafungin treatment was 60%. Also, the research by Bochennek et al. 
(Bochennek et al., 2015) refers to children treated for Acute Lymphoblastic Leukemia 
(ALL), Acute Myeloid Leukemia (AML), and acute high-risk relapse, as well as 
children undergoing allogeneic hematopoietic stem cell transplantation. In this case, the 
administration does not take place through daily intravenous infusions, but biweekly, 
this element represents the exception compared to other studies. The dose, in this case, 
is 3-4 mg/kg/day. 
The evidence of Buck M. (Buck M., 2014) refers to a trial of the University of Virginia 
School of Medicine, in particular, is made to the classification of patient weight and 
pharmacokinetic data, in particular, the study concerning the use of micafungin takes 
into account children (from 4 months to 16 years) with a weight of less than 30 kg. In 
the first case the dose of the drug was daily and equal to 1, 2, 3 mg/kg/ day; children 
weighing more than 30 kg received a daily dose of 1, 2, 2.5 mg/kg/ day.  Our systematic 
review also includes the elements of evaluation concerning the cost-effectiveness of the 
treatment (table 2). This information makes it possible to verify the number of resources 
invested in the treatment of candidiasis. The economic information allows evaluating 
the concept of efficiency understood as the maximum value obtainable and the result 
achieved for each unit of expenditure (Zilberger M. D. & Shorr A. F., 2010). The search 
criteria used allowed to obtain only one result referred to the cost-effectiveness in the 
use of micafungin. According to the analysis by Santolaya Maria E. et all.  (Santolaya 
Maria E. et al., 2013) which considers 1118 hospital admissions for candidiasis, 
children suffering from this disease have a time of hospitalization equal to 44.8 days 
against an average period of 23.7 days in case of absence. The value of direct and 
indirect costs for a patient with candidiasis is $ 183,645 compared to a cost of $ 91,379 
for patients hospitalized but without candidemia (T. E. Zaoutis et al., 2005). This 
creates an increase in hospitalization days averaging 21.1 and costs of $ 92.266. In the 
end, the research team provides a timeline of the analyses included in the systematic 
review. In the case of newborns, 50% of the results are before 2013, and only 3 elements 
are more recent. Studies concerning the use of micafungin in pediatric age, on the other 
hand, confirm greater attention in recent years, in particular, 75% of the results were 
published after 2013, only 25% before this year. 
European journal of volunteering and community-based projects Vol.1, No 1; 2020 
ISSN: 2724-0592 
Published by Odv Casa Arcobaleno 
106 
 
 
Figure 2. Search results per year 
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Table 1. Studies characteristics for micafungin in neonates and children. The table summarizes the main characteristics of the different studies 
regarding the number of clinical studies, country, target population, stage of disease, micafungin dose, additional information, duration of 
treatment, successful rate/conclusion and year. 
Source 
Number of 
clinical 
studies 
Country 
Target 
population 
Stage of 
disease 
Micafungin dose Additional 
information 
Duration of 
treatment 
Successful rate - 
Conclusion 
Yea
r 
(Arrieta et 
al., 2011) 296 
Europe, 
USA and 
Asia 
Neonates: < 
4 weeks and 
Children (0 - 
16) years 
Candidiasis 0.4 - 8.6 mg/kg/day 
and 0.8 - 7.7 
mg/kg/day 
40% of 
patients are 
neutropenic 
15 days Micafungin was 
well tolerated by 
children at all ages 
including those with 
life-threatening 
underlying 
conditions. 
2011 
(Bochennek 
et al., 2015) 21 UK 
Children (0.2 
- 16) years 
Invasive 
fungal disease 
3 - 4 mg/kg/twice 
weekly 
Na 20 - 313 days 
 
Approved dosages 2015 
(Buck M., 
2014) 229 USA 
Children (4 
months - 16 
years) 
Candidadias 
(Acute, 
Esophageal, 
Infections in 
HSCT 
Recipients) 
1 - 2 - 3 mg/kg/day 
and 1 - 2 - 2.5 
mg/kg/day 
Weight < 30 
kg and Weight 
> 30 kg 
Na Na 2014 
(Hope et al., 
2010) 47+18 UK 
Neonates 
26.8 weeks 
and Infants 
Systemic 
candidiasis 
Suspected or 
proven 
disseminated 
candidiasis 
Loading dose 15 
mg/kg/day - 
maintenance dose 10 
mg/kg/day (neonates) 
0,75 - 15 mg/kg/day 
(infants) 
Weight: 
640.0–4615.0 
g (Neonates) 
Weight: 0.54 - 
4.5 kg 
(Infants) 
5 days - max 45 
days (validated by 
the doctor and 
based on 
maintenance dose) 
for Infants 
No adverse event 
associated 
(neonates) - 82,6% 
(infants) 
2010 
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Table 1. Continued.  
Source 
Number of 
clinical 
studies 
Country 
Target 
population 
Stage of disease Micafungin 
dose 
Additional 
information 
Duration of 
treatment 
Successful rate - 
Conclusion 
Year 
(Kawaguchi 
et al., 2009) 4 USA 
Premature 
Neonates mean 
27weeks 0.9 - 
24,1 weeks 
Premature infants 
diagnosed with 
Candida infections 
0,5 - 1.0 
mg/kg/day 
Weight: 579,3 g 
(± 80.5 g) 
3.1 - 9.8 days Effective and tolerable 2009 
(Kobayashi 
et al., 2015) 201 Japan 
Children (0 - 
16) years 
Candidiasis 1 mg/kg/day 
up to 6 
mg/kg/day 
Na 19.7 days 88,20% 2015 
(Kovanda et 
al., 2018) 12+27 Europe 
Neonates (3 -
119) days 
45% of invasive 
candidiasis 
2 - 10 
mg/kg/day 
Weight: 0.5 - 
4,8 kg 
1 to 34 days 
(14 days) 
73% - 83% 2018 
(Maximova 
et al., 2017) 
 
47+18 Italy 
Children (0 - 
17) years - 
Neonates mean 
2.33 months 
Hematopoietic 
stem cell 
transplantation 
(HSCT) patients - 
Systemic 
candidiasis 
mean 105.9 +- 
28.9 
mg/m2/day - 8 
- 15 
mg/kg/day 
Treatment with 
micafungine 
began 3 days 
after 
transplantation - 
Weight: 3,24 kg 
13.1 - 30.1 
days 
87,2% (children) - 
78,20% (infants) 
2017 
(Queiroz-
Telles et al., 
2008) 
48 USA 
Neonates and 
children (0 - 16) 
years 
Na 2 mg/kg/day Na 15 days 72,90% 2008 
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Table 1. Continued. 
Source 
Number of 
clinical 
studies 
Country 
Target 
population 
Stage of disease Micafungin 
dose 
Additional information Duration of 
treatment 
Successful 
rate - 
Conclusion 
Year 
(Santolaya 
Maria E. et 
al., 2013) 
88 Latin America 
Children (0,2 - 
18 years) 
Invasive; after 4 days 
of antibacterial therapy 
that continued with 
fever and neutropenia 
2 mg/kg/day 
if the body 
weight is 
<=40 kg 
The study recommends 
that the dose can be 
increased up to 4 mg / kg 
/ day if the response to the 
drug is not appropriate for 
patients weighing <= 40 
kg. 
14 days after 
the first 
negative blood 
culture and 
after the 
clinical 
resolution of 
the infection. 
Na 2013 
(Santolaya 
et al., 2013) 213 
Latin 
America 
Neonates <= 
28 days 
Invasive 0,75-3.0 
mg/kg with a 
body weight 
>1000 g 
(Heresi et al., 
2006) 
15 mg/kg/day once daily, 
success treatment in 7 
days (Queiroz-Telles et 
al., 2008) 
14 days after 
the first 
negative blood 
culture and 
after the 
clinical 
resolution of 
the infection. 
57,10% 2013 
(Styczynski 
et al., 2016) 12 USA 
Neonates mean 
27weeks 
Suspected systemic 
infections 
15 
mg/kg/day 
Weight: 775 g 5 days Na 2009 
(Styczynski 
et al., 2016) 63+30 Poland 
Children (0,1 - 
19) years and 
Children (0,2 - 
17,8) years 
Pediatric hemato-
oncology (PHO) and 
Hematopoietic stem 
cell transplantation 
(HSCT) patients 
1 - 2 
mg/kg/day 
The 63 patients come 
from 4.2 months of acute 
leukemia therapy, while 
the other 30 comes from 
2.3 months of cure for 
HSCT. 
11 days (PHO) 
and 15 days 
(HSCT) 
85% (PHO) - 
60% (HSCT) 
2016 
European journal of volunteering and community-based projects Vol.1, No 1; 2020 
ISSN: 2724-0592 
Published by Odv Casa Arcobaleno  
110 
 
Table 2. Economic evaluations referred to micafungin treatment for pediatric patients. 
   Increase days of hospitalization 
Increase in total per-
patient hospital charges 
  
Source Country Age 
Hospital 
admission 
Number 
of days 
minimum 
Number 
of days 
maximum 
Minimum value Maximum 
value 
Year 
(T. 
Zaoutis, 
2010) 
USA 
1 to 
18 
years 
old 
1118 
patients 
14.4 27.8 65,058$ 119,474$ 2005 
 
 
4. Discussion 
The 13 medical articles characterize the scientific evidence and focus exclusively on the clinical 
features related to the diagnosis and pharmacokinetics of micafungin. The intrinsic nature and the 
applicability of the drug have allowed creating different interpretations to study the effects of children 
both in neonatal and pediatric age. 
The analysis reported studies that selected patients not only under conditions of stable candidiasis but 
also invasive or exposed to organ transplants or neutropenic patients.  
The articles that analyse in their studies the effects of the drug in newborns consider a period of birth 
between a few days and 24 weeks (Arrieta et al., 2011; Hope et al., 2010; Kawaguchi et al., 2009; 
Kovanda et al., 2018; Maximova et al., 2017; Queiroz-Telles et al., 2008; Santolaya et al., 2013; 
Smith et al., 2009; Steinbach, 2016) and reflect a level of administration up to 10 mg/kg/day. 
Only two results deal with the analysis and efficacy of micafungin in infants younger than one month 
of life  (Kovanda et al., 2018; Santolaya et al., 2013), in these cases the initial dose is fixed in 2 
mg/kg/day with a possible increase up to 15 mg/ kg/day in order to mitigate the risks from 
overexposure to candidiasis (Queiroz-Telles et al., 2008). The frequency of drug administration in 
these results is always daily. 
The remaining sample deals with effects in children aged one to 19 years (Arrieta et al., 2011; 
Bochennek et al., 2015; Buck M., 2014; Kobayashi et al., 2015; Queiroz-Telles et al., 2008; Santolaya 
Maria E. et al., 2013; Styczynski et al., 2016). These cases have lower amounts of drug intake 
compared to newborns; inversely there is an increase in the duration of treatment. The reported cases 
present a frequency of administration mostly daily with a single bi-weekly administration element. 
In addition, the two articles of Santolaya Maria E. et al and Santolaya et al. (Santolaya et al., 2013; 
Santolaya Maria E. et al., 2013) discuss the direct issue of the treatment of candidiasis in infants and 
children respectively in the case of standard prophylaxis, and in case of invasive treatments for 
advanced diseases. The approach that is shown, in a first phase, in fact, consists in a real action of 
detecting risks and subsequently mitigating them; key elements to reducing the incidence of the 
disease and associated costs (T. E. Zaoutis et al., 2005).  
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The main limitation of the study consisted of the low number of cost-effectiveness analyses not yet 
present for the target object of study. The economic analysis in these cases allows to evaluate better 
and make decisions essential for the correct application of care; even in the healthcare world, 
economic analysis can support choices, especially in a context of scarcity of resources (Zilberger M. 
D. & Shorr A. F., 2010). 
 
5. Conclusions 
The condition of candidiasis still shows a very high percentage of incidence, the most worrying values 
concern the newborns who have mortality rates between 40% and 50%. 
The use of echinocandins including micafungin allows clinicians to manage the disease and obtain 
response rates that increase in the case of initial and newly diagnosed candidiasis and decrease for 
the most severe cases. 
What emerges from the literature included in the systematic analysis is a high and multidimensional 
clinical knowledge regarding neonatal and pediatric age that also includes invasive levels of elevated 
candidiasis. A different case is the analysis of cost-effectiveness, limited in this case to a single result 
which, however, shows how the incidence of the disease leads to an increase in hospital management 
costs of 49.76% compared to non-patients. affected by this pathology; this, therefore, involves very 
high costs due both to the increase in the days of hospitalization of patients and to the administration 
of micafungin (T. E. Zaoutis et al., 2005). 
The aim of the research was to highlight how the drug is used in infants and children and what hospital 
costs are associated with candida treatment. 
In conclusion, the review highlights that: 
- micafungin is used in newborns to treat candida with a dose between 0.4 and 10 mg/kg/day on 
average for 15 days;  
- micafungin is used in newborns with invasive candida with a higher dose of between 8 and 15 
mg/kg/day with a treatment period varying between 5 and 45 days;  
- micafungin is used in children with candida with a dose between 0.8 and 7.7 mg/kg/day with a 
duration between 15 and 19.7 days. This also happens in the case of invasive candida but with a 
treatment period between 14 and 313 days; 
- the cost-effectiveness analysis shows that the incidence of costs for candidiasis cases is about 50% 
higher compared to neonatal and pediatric patients not affected by candidiasis (T. E. Zaoutis et al., 
2005);  
- the high rates of mortality and high costs require the adoption of effective measures to prevent and 
treat the disease. 
What is hoped for is to provide a more comprehensive picture of the use of the drug from a clinical 
point of view; the aim is to act promptly to eradicate the disease by increasing patients' survival and 
decreasing the associated costs. 
 
 
 
European journal of volunteering and community-based projects Vol.1, No 1; 2020 
ISSN: 2724-0592 
Published by Odv Casa Arcobaleno  
112 
 
References 
Arrieta, A. C., Maddison, P., & Groll, A. H. (2011). Safety of micafungin in pediatric clinical trials. 
The Pediatric Infectious Disease Journal, 30(6), e97–e102. 
https://doi.org/10.1097/INF.0b013e3182127eaf 
Benjamin, D. K., DeLong, E., Cotten, C. M., Garges, H. P., Steinbach, W. J., & Clark, R. H. (2004). 
Mortality Following Blood Culture in Premature Infants: Increased with Gram-negative Bacteremia 
and Candidemia, but Not Gram-positive Bacteremia. Journal of Perinatology, 24(3), 175–180. 
https://doi.org/10.1038/sj.jp.7211068 
Benjamin, D. K., Stoll, B. J., Fanaroff, A. A., McDonald, S. A., Oh, W., Higgins, R. D., Duara, S., 
Poole, K., Laptook, A., & Goldberg, R. (2006). Neonatal Candidiasis Among Extremely Low Birth 
Weight Infants: Risk Factors, Mortality Rates, and Neurodevelopmental Outcomes at 18 to 22 
Months. Pediatrics, 117(1), 84–92. https://doi.org/10.1542/peds.2004-2292 
Benjamin, D. K., Stoll, B. J., Gantz, M. G., Walsh, M. C., Sánchez, P. J., Das, A., Shankaran, S., 
Higgins, R. D., Auten, K. J., Miller, N. A., Walsh, T. J., Laptook, A. R., Carlo, W. A., Kennedy, K. 
A., Finer, N. N., Duara, S., Schibler, K., Chapman, R. L., Van Meurs, K. P., … Eunice Kennedy 
Shriver National Institute of Child Health and Human Development Neonatal Research Network. 
(2010). Neonatal candidiasis: Epidemiology, risk factors, and clinical judgment. Pediatrics, 126(4), 
e865-873. https://doi.org/10.1542/peds.2009-3412 
Blyth, C. C., Chen, S. C. A., Slavin, M. A., Serena, C., Nguyen, Q., Marriott, D., Ellis, D., Meyer, 
W., & Sorrell, T. C. (2009). Not Just Little Adults: Candidemia Epidemiology, Molecular 
Characterization, and Antifungal Susceptibility in Neonatal and Pediatric Patients. Pediatrics, 123(5), 
1360–1368. https://doi.org/10.1542/peds.2008-2055 
Bochennek, K., Balan, A., Müller-Scholden, L., Becker, M., Farowski, F., Müller, C., Groll, A. H., 
& Lehrnbecher, T. (2015). Micafungin twice weekly as antifungal prophylaxis in paediatric patients 
at high risk for invasive fungal disease. The Journal of Antimicrobial Chemotherapy, 70(5), 1527–
1530. https://doi.org/10.1093/jac/dku544 
Buck M. (2014). Micafungin Use in the Treatment of Neonatal and Pediatric Fungal Infections. 4. 
Greenberg, R. G., & Benjamin, D. K. (2014). Neonatal candidiasis: Diagnosis, prevention, and 
treatment. The Journal of Infection, 69 Suppl 1, S19-22. https://doi.org/10.1016/j.jinf.2014.07.012 
Heresi, G. P., Gerstmann, D. R., Reed, M. D., van den Anker, J. N., Blumer, J. L., Kovanda, L., 
Keirns, J. J., Buell, D. N., & Kearns, G. L. (2006). The pharmacokinetics and safety of micafungin, 
a novel echinocandin, in premature infants. The Pediatric Infectious Disease Journal, 25(12), 1110–
1115. https://doi.org/10.1097/01.inf.0000245103.07614.e1 
Hill, A. V. S. (1998). The Immunogenetics of Human Infectious Diseases. Annual Review of 
Immunology, 16(1), 593–617. https://doi.org/10.1146/annurev.immunol.16.1.593 
Hope, W. W., Smith, P. B., Arrieta, A., Buell, D. N., Roy, M., Kaibara, A., Walsh, T. J., Cohen-
Wolkowiez, M., & Benjamin, D. K. (2010). Population Pharmacokinetics of Micafungin in Neonates 
and Young Infants. Antimicrobial Agents and Chemotherapy, 54(6), 2633–2637. 
https://doi.org/10.1128/AAC.01679-09 
European journal of volunteering and community-based projects Vol.1, No 1; 2020 
ISSN: 2724-0592 
Published by Odv Casa Arcobaleno  
113 
 
Kawaguchi, C., Arai, I., Yasuhara, H., Sano, R., Nishikubo, T., & Takahashi, Y. (2009). Efficacy of 
micafungin in treating four premature infants with candidiasis. Pediatrics International, 51(2), 220–
224. https://doi.org/10.1111/j.1442-200X.2008.02726.x 
Kobayashi, C., Hanadate, T., Niwa, T., Yoshiyasu, T., So, M., & Matsui, K. (2015). Safety and 
Effectiveness of Micafungin in Japanese Pediatric Patients: Results of a Postmarketing Surveillance 
Study. Journal of Pediatric Hematology/Oncology, 37(5), e285–e291. 
https://doi.org/10.1097/MPH.0000000000000343 
Kovanda, L. L., Walsh, T. J., Benjamin, D. K., Arrieta, A., Kaufman, D. A., Smith, P. B., Manzoni, 
P., Desai, A. V., Kaibara, A., Bonate, P. L., & Hope, W. W. (2018). Exposure-Response Analysis of 
Micafungin in Neonatal Candidiasis: Pooled Analysis of Two Clinical Trials. The Pediatric Infectious 
Disease Journal, 37(6), 580–585. https://doi.org/10.1097/INF.0000000000001957 
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., 
Devereaux, P. J., Kleijnen, J., & Moher, D. (2009). The PRISMA Statement for Reporting Systematic 
Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and 
Elaboration. PLoS Medicine, 6(7), e1000100. https://doi.org/10.1371/journal.pmed.1000100 
Makhoul, I. R., Sujov, P., Smolkin, T., Lusky, A., & Reichman, B. (2002). Epidemiological, Clinical, 
and Microbiological Characteristics of Late-Onset Sepsis Among Very Low Birth Weight Infants in 
Israel: A National Survey. Pediatrics, 109(1), 34–39. https://doi.org/10.1542/peds.109.1.34 
Manzoni, P., Wu, C., Tweddle, L., & Roilides, E. (2014). Micafungin in premature and non-
premature infants: A systematic review of 9 clinical trials. The Pediatric Infectious Disease Journal, 
33(11), e291-298. https://doi.org/10.1097/INF.0000000000000434 
Maximova, N., Schillani, G., Simeone, R., Maestro, A., & Zanon, D. (2017). Comparison of Efficacy 
and Safety of Caspofungin Versus Micafungin in Pediatric Allogeneic Stem Cell Transplant 
Recipients: A Retrospective Analysis. Advances in Therapy, 34(5), 1184–1199. 
https://doi.org/10.1007/s12325-017-0534-7 
Queiroz-Telles, F., Berezin, E., Leverger, G., Freire, A., van der Vyver, A., Chotpitayasunondh, T., 
Konja, J., Diekmann-Berndt, H., Koblinger, S., Groll, A. H., Arrieta, A., & Micafungin Invasive 
Candidiasis Study Group. (2008). Micafungin versus liposomal amphotericin B for pediatric patients 
with invasive candidiasis: Substudy of a randomized double-blind trial. The Pediatric Infectious 
Disease Journal, 27(9), 820–826. https://doi.org/10.1097/INF.0b013e31817275e6 
Santolaya, M. E., Alvarado Matute, T., de Queiroz Telles, F., Colombo, A. L., Zurita, J., Tiraboschi, 
I. N., Cortes, J. A., Thompson-Moya, L., Guzman-Blanco, M., Sifuentes, J., Echevarría, J., & Nucci, 
M. (2013). Recommendations for the management of candidemia in neonates in Latin America. 
Revista Iberoamericana de Micología, 30(3), 158–170. https://doi.org/10.1016/j.riam.2013.05.012 
Santolaya Maria E., de Queiroz Telles F., Alvarado Matute T., Colombo A. L., Zurita J., J., 
Tiraboschi, I. N., Cortes, J. A., Thompson-Moya, L., Guzman-Blanco, M., Sifuentes, J., Echevarría, 
J., & Nucci, M. (2013). Recommendations for the management of candidemia in children in Latin 
America. Revista Iberoamericana de Micología, 30(3), 171–178. 
https://doi.org/10.1016/j.riam.2013.05.010 
Smith, P. B., Walsh, T. J., Hope, W., Arrieta, A., Takada, A., Kovanda, L. L., Kearns, G. L., Kaufman, 
D., Sawamoto, T., Buell, D. N., & Benjamin, D. K. (2009). Pharmacokinetics of an Elevated Dosage 
European journal of volunteering and community-based projects Vol.1, No 1; 2020 
ISSN: 2724-0592 
Published by Odv Casa Arcobaleno  
114 
 
of Micafungin in Premature Neonates. The Pediatric Infectious Disease Journal, 28(5), 412–415. 
https://doi.org/10.1097/INF.0b013e3181910e2d 
Steinbach, W. J. (2016). Pediatric Invasive Candidiasis: Epidemiology and Diagnosis in Children. 
Journal of Fungi, 2(1). https://doi.org/10.3390/jof2010005 
Styczynski, J., Czyzewski, K., Wysocki, M., Zajac-Spychala, O., Wachowiak, J., Ociepa, T., 
Urasinski, T., Gryniewicz-Kwiatkowska, O., Kolodziejczyk-Gietka, A., Dembowska-Baginska, B., 
Perek, D., Salamonowicz, M., Hutnik, L., Matysiak, M., Siewiera, K., Frackiewicz, J., Kalwak, K., 
Badowska, W., Malas, Z., … Gil, L. (2016). Micafungin in invasive fungal infections in children with 
acute leukemia or undergoing stem cell transplantation. Leukemia & Lymphoma, 57(10), 2456–2459. 
https://doi.org/10.3109/10428194.2016.1143937 
Sucher, A. J., Chahine, E. B., & Balcer, H. E. (2009). Echinocandins: The newest class of antifungals. 
The Annals of Pharmacotherapy, 43(10), 1647–1657. https://doi.org/10.1345/aph.1M237 
Zaoutis, T. (2010). Candidemia in children. Current Medical Research and Opinion, 26(7), 1761–
1768. https://doi.org/10.1185/03007995.2010.487796 
Zaoutis, T. E., Argon, J., Chu, J., Berlin, J. A., Walsh, T. J., & Feudtner, C. (2005). The Epidemiology 
and Attributable Outcomes of Candidemia in Adults and Children Hospitalized in the United States: 
A Propensity Analysis. Clinical Infectious Diseases, 41(9), 1232–1239. 
https://doi.org/10.1086/496922 
Zilberger M. D., & Shorr A. F. (2010). Understanding cost-effectiveness. Clinical Microbiology and 
Infection, 16(12), 1707–1712. https://doi.org/10.1111/j.1469-0691.2010.03331.x 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
